Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyWed, 17 Jul 2024 03:57:09 +0200Thu, 27 Jun 2024 15:46:06 +0200Human medicines European public assessment report (EPAR): Adcetris, brentuximab vedotin, Date of authorisation: 25/10/2012, Revision: 35, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/adcetrisHuman medicines European public assessment report (EPAR): Adcetris, brentuximab vedotin, Date of authorisation: 25/10/2012, Revision: 35, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/adcetrisThu, 27 Jun 2024 15:46:06 +0200Human medicineOrphan designation: monoclonal antibody against human CD30 covalently linked to the cytotoxin monomethylauristatin E (brentuximab vedotin) Treatment of Hodgkin's lymphoma, 15/01/2009 Withdrawnhttps://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-596Orphan designation: monoclonal antibody against human CD30 covalently linked to the cytotoxin monomethylauristatin E (brentuximab vedotin) Treatment of Hodgkin's lymphoma, 15/01/2009 Withdrawnhttps://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-596Wed, 26 Jun 2024 17:30:00 +0200Human medicineWithdrawn application: Adcetris, 23/02/2024https://www.ema.europa.eu/en/medicines/human/variation/adcetrisWithdrawn application: Adcetris, 23/02/2024https://www.ema.europa.eu/en/medicines/human/variation/adcetrisFri, 22 Mar 2024 12:00:00 +0100Human medicineAdcetris : EPAR - Procedural steps taken and scientific information after authorisationhttps://www.ema.europa.eu/system/files/documents/procedural-steps-after/h-2455-steps-after_en_0.pdfAdcetris : EPAR - Procedural steps taken and scientific information after authorisationhttps://www.ema.europa.eu/system/files/documents/procedural-steps-after/h-2455-steps-after_en_0.pdfFri, 01 Dec 2023 16:51:00 +0100Human medicine